BioCentury
ARTICLE | Company News

ProStrakan in Novartis, Cellegy deals

September 28, 2006 1:01 AM UTC

ProStrakan (LSE:PSK) granted Novartis (NVS; SWX:NOVN) an exclusive worldwide license to a patent estate that allows NVS to research, develop and commercialize its preclinical MAbs against an undisclosed PSK target to treat bone-related diseases. PSK will receive a total of $5.8 million in an undisclosed upfront payment and R&D payments over the first two years. PSK also is eligible for more than $140 million in milestones, plus royalties. NVS is responsible for all development, manufacture, clinical and regulatory costs and commercialization. PSK retains rights to small molecules against the target. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article